)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
Chosa Oncology
Chosa Oncology (CHOSA) investor relations material
Chosa Oncology Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary26 Feb, 2026
Executive summary
Q4 2025 marked a transformative period with significant scientific, strategic, and financial progress, including new patent filings and clinical data supporting Platin-DRP® in predicting synergy between platinum therapy and immunotherapy.
Expansion of Platin-DRP®'s clinical utility to predict overall survival in NSCLC patients, doubling its addressable market potential.
Strengthened financial position through a directed share issue of approximately 7.3 MSEK after the reporting period.
Financial highlights
Full-year result after financial items: -5,611 TSEK (2024: -4,772 TSEK); Q4 result: 699 TSEK (2024 Q4: 519 TSEK).
Earnings per share after dilution: -0.07 SEK for the year (unchanged YoY); Q4: 0.009 SEK (2024 Q4: 0.007 SEK).
Equity ratio at year-end: 82% (2024: 83%).
Cash and cash equivalents at year-end: 1,791 TSEK (2024: 6,438 TSEK).
Total assets: 20,252 TSEK (2024: 21,402 TSEK).
Outlook and guidance
Ongoing focus on expanding partnerships with pharma and biotech for Platin-DRP® as a companion diagnostic.
Continued clinical validation and regulatory preparations supported by new capital.
Strategic aim to commercialize both Platin-DRP® and LiPlaCis through licensing, partnerships, and direct sales.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Chosa Oncology
- Precision platform targets major efficacy gains in cancer therapy, with key data and funding milestones ahead.CHOSA
Investor Update25 Nov 2025 - Significant clinical progress and strengthened financial position with new capital raised in Q3 2025.CHOSAQ3 202513 Nov 2025
- Strong Q2 results, clinical progress, and capital raises position for key data in Q3 2025.CHOSAQ2 202528 Aug 2025
- Q3 net loss narrowed, financials strengthened, and board expertise expanded with Prof. Hirsch.CHOSAQ3 202413 Jun 2025
- Q2 loss narrowed and cash reserves grew as CHOSA advanced oncology partnerships and technology.CHOSAQ2 202413 Jun 2025
- DRP® platform expansion and clinical progress drive CHOSA Oncology's Q1 2025 focus.CHOSAQ1 20256 Jun 2025
- Annual loss narrows as CHOSA deepens clinical alliances and pursues commercialization.CHOSAQ4 20246 Jun 2025
Next Chosa Oncology earnings date
Status update26 Mar, 2026
Chosa Oncology
Next Chosa Oncology earnings date
Status update26 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage